Selection of Tumor-binding Ligands in Cancer Patients with Phage Display Libraries

Abstract

Phage display has been used extensively in vitro and in animal models to generate ligands and to identify cancer-relevant targets. We report here the use of phage-display libraries in cancer patients to identify tumor-targeting ligands. Eight patients with stage IV cancer, including breast, melanoma, and pancreas, had phage-displayed random peptide or scFv library (1.6 Â 10 8 -1 Â 10 11 transducing units/kg) administered i.v.; tumors were excised after 30 minutes; and tumor-homing phage were recovered. In three patients, repeat panning was possible using phage recovered and amplified from that same patient's tumor. No serious side effects, including allergic reactions, were observed with up to three infusions. Patients developed antiphage antibodies that reached a submaximal level within the 10-day protocol window for serial phage administration. Tumor phage were recoverable from all the patients. Using a filter-based ELISA, several clones from a subset of the patients were identified that bound to a tumor from the same patient in which clones were recovered. The clone-binding to tumor was confirmed by immunostaining, bioassay, and real-time PCR-based methods. Binding studies with noncancer and cancer cell lines of the same histology showed specificity of the tumor-binding clones. Analysis of insert sequences of tumor-homing peptide clones showed several motifs, indicating nonrandom accumulation of clones in human tumors. This is the first reported series of cancer patients to receive phage library for serial panning of tumor targeting ligands. The lack of toxicity and the ability to recover clones with favorable characteristics are a first step for further research with this technology in cancer patients. (Cancer Res 2006; 66(15): 7724-33)

Deep, noninvasive imaging and surgical guidance of submillimeter tumors using targeted M13-stabilized single-walled carbon nanotubes

“…delivery, and optical emission in NIR2 in a preclinical mouse model of ovarian cancer. Our acute toxicity studies are consistent with several other preliminary studies exploring the safety of M13 and SWNTs, in that a panel of serum biomarkers were not elevated (30)(31)(32)(33). Collectively, we believe these findings suggest that these materials warrant further consideration for clinical translation, which would include the development of instruments for real-time imaging, outcomes research such as survival studies in preclinical models, and rigorous safety evaluation through the National Characterization Laboratory (National Cancer Institute) and others to assess long-term trafficking and clearance of these materials as well as chronic toxicity studies.…”

Phage display and molecular imaging: expanding fields of vision in living subjects

“…In vivo homing methodology has been expanded to select for phage clones that can extravasate from the vasculature and penetrate into tumors (Newton et al 2006), and for phage clones specific for atherosclerotic plaques (Kelly et al 2006b), among other tissue. Furthermore, in vivo homing has also been applied to human subjects (Arap et al 2002;Krag et al 2006). To refine in vivo homing protocols, a thorough biodistribution study with immunodeficient mice was performed, and circulation time was found to be a critical variable, depending on the organ or tissue being targeted (Zou et al 2004).…”

Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

“…Results from several Phase I and II trials have been reported, and a number of trials are currently ongoing or at the stage of recruiting patients for trials. 63,[81][82][83][84] The results of clinical trials so far have been very encouraging, with reports of improved outcomes in terms of therapeutic efficacy, such as the absence of any dose-limiting toxicity and good tolerance of all peptide-targeted therapy combinations. 67 The most widely used peptides in the targeted-delivery applications are integrin-targeting RGD-peptides -the first tumor-targeting peptides discovered.…”